CEO Total Pay
$3.4M
FY2023 Summary Compensation, below median
GTHX FY2023 SEC EDGAR DEF 14A
G1 Therapeutics, Inc. CEO pay ratio
The CEO earned $3.4M in FY2023 against median worker pay of $281,293 · Chemicals & Pharmaceuticals.
- State
- DE
- Filing date
- 2024-04-25
- Industry
- Chemicals & Pharmaceuticals
- Fiscal year
- FY2023
Data updated August 2026
Subscribe to G1 Therapeutics, Inc. CEO pay filing updates (RSS)
CEO-to-worker pay ratio
12:1
Below Average (Scale: 0–1000:1)
CEO pay
$3.4M
Median worker
$281,293
Latest filing FY2023. This company's newest DEF 14A on file is for FY2023, not FY2025, so the figures on this page are from that earlier year and are not ranked against the FY2025 industry benchmark. Industry pages mark issuers like this one with a "Latest filing" label.
Answer first
G1 Therapeutics, Inc. reported a 12:1 CEO-to-worker pay ratio in FY2023 - at or below the Chemicals & Pharmaceuticals median of 42:1 across 168 filers.
Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.
- Pay ratio
- 12:1
- FY2023 disclosed
- CEO total
- $3.4M
- Summary Compensation Table total
- Median worker
- $281,293
- Dodd-Frank median employee
Ratio bands among Chemicals & Pharmaceuticals peers
Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.
CEO Compensation Breakdown, FY2023
A component-level pay breakdown is not reported in G1 Therapeutics, Inc.'s structured SEC pay-ratio disclosure. See our methodology →
Filing-year trail · G1 Therapeutics, Inc.
Complete DEF 14A pay-ratio filings for this CIK across FY2021–2023. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).
- Latest ratio
- 12:1
- FY2023
- vs prior FY
- 0:1
- from FY2022 12:1
- CEO $ YoY
- +15%
- $3.4M latest
- Filings shown
- 3
- FY2021–2023
| FY | CEO pay | Δ pay | Median worker | Pay ratio | Δ ratio |
|---|---|---|---|---|---|
| 2021 | $8.7M | - | $198,441 | 44:1 | - |
| 2022 | $2.9M | -66% | $243,930 | 12:1 | -32:1 |
| 2023 | $3.4M | +15% | $281,293 | 12:1 | 0:1 |
Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1560241, FY2021–2023. Adjacent-year deltas only.
Industry Comparison - Chemicals & Pharmaceuticals
This Company's Ratio
12:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$3.4M
Companies in Industry
168
vs. Industry Median
Below
G1 Therapeutics, Inc.: near-parity Item 402(u) ratio
G1 Therapeutics, Inc. stamps FLOOR · ELITE-MED at 12:1 against $281,293 median worker pay in FY2023. the CEO earned 12× the median employee ($281,293) in FY2023.
At $281,293 median worker pay, the FLOOR stamp is near pay-parity territory under MID$ CEO total.
Pay Ratio
12:1
Below typical
What FY2023 shows for G1 Therapeutics, Inc.
G1 Therapeutics, Inc. stamps FLOOR · ELITE-MED at 12:1 against $281,293 median worker pay in FY2023. The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; G1 Therapeutics, Inc.'s $3.4M CEO total is at or below the $7.9M industry median CEO pay.
G1 Therapeutics, Inc. stamps FLOOR · MID$ · ELITE-MED; grant-date fair value (not realized pay) is what the DEF 14A reports. Open Chemicals & Pharmaceuticals peers.
Key Data, FY2023
- Total Compensation
- $3.4M
- Median Employee Pay
- $281,293
- Pay Ratio
- 12:1
- Filing Date
- 2024-04-25
Company Info
- Ticker
- GTHX
- CIK
- 1560241
- Industry
- Chemicals & Pharmaceuticals
- SIC Code
- 2834
- State
- DE
SEC EDGAR DEF 14A for CIK 1560241, FY2023. Informational only, not investment advice. Verify on EDGAR.
Read our methodology - how this data is sourced, computed, and verified. G1 Therapeutics, Inc. stamps FLOOR · ELITE-MED at 12:1 against $281,293 median worker pay in FY2023.
Read with G1 Therapeutics, Inc.
ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps FLOOR · MID$ · ELITE-MED.
U S Physical Therapy Inc /NV · MID$
ABS(ceo_total_comp) peer at $3.4M (Δ $3K lighter vs G1 Therapeutics, Inc.); FLOOR · PAR-MED vs this page's FLOOR · MID$ · ELITE-MED.
Veeva Systems Inc · MID$
ABS(ceo_total_comp) peer at $3.4M (Δ $9K lighter vs G1 Therapeutics, Inc.); FLOOR · ELITE-MED vs this page's FLOOR · MID$ · ELITE-MED.
Dollar Tree, Inc. · MID$
ABS(ceo_total_comp) peer at $3.4M (Δ $9K lighter vs G1 Therapeutics, Inc.); STEEP · LOW-MED vs this page's FLOOR · MID$ · ELITE-MED.
Wolverine World Wide Inc /de/ · MID$
ABS(ceo_total_comp) peer at $3.4M (Δ $10K lighter vs G1 Therapeutics, Inc.); MODEST · PAR-MED vs this page's FLOOR · MID$ · ELITE-MED.
Chemicals & Pharmaceuticals benchmark
G1 Therapeutics, Inc. stamps FLOOR · MID$ · ELITE-MED inside SIC 28 - open the industry median board after the ABS peers.
Pay-ratio rankings · FLOOR
See where FLOOR · MID$ packages sit on the national leaderboard after reading G1 Therapeutics, Inc..
Ratio primer · FLOOR
G1 Therapeutics, Inc.'s FLOOR stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for G1 Therapeutics, Inc. (CIK 1560241), FY2023. See our methodology. Aggregated by PlainCEOPay as of August 2026.
Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.